The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.
Perjeta was approved in 2012 by the EU for the treatment of patients with advanced or late-stage (metastatic) HER2-positive breast cancer. HER2-positive breast cancers have increased amounts of the HER2 protein that contributes to cancer cell growth and survival.
Continue reading the FDA NEWS RELEASE, 30 Sept 2013.
All our posts tagged Breast Cancer – Drugs – FDA.
2 thoughts on “Perjeta pre-Surgery Breast Cancer Drug approved by the FDA as neoadjuvant Breast Cancer Treatment”
Reblogged this on Laitom's Blog.
many thanks Tom